Scarica l'app Stockscreener
29.94
1.87%
-0.57
Dopo l'orario di chiusura:
30.03
0.09
+0.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. - The Motley Fool
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts - Yahoo Finance Singapore
3 Emerging Biotech Stocks With Significant Upside Potential - Yahoo Finance
Free cash flow of Viking Therapeutics, Inc. – HAN:1VT - TradingView
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - theglobeandmail.com
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - The Motley Fool
3 Non-AI Growth Stocks That Have Massive Upside - Yahoo Finance
VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks - TradingView
Viking Therapeutics (VKTX) Raises $575M in Upsized Stock and Con - GuruFocus
Viking Completes $575 Million Financing Round - Intellectia AI
Form 8K Viking Therapeutics Inc For: 28 September By Investing.com - Investing.com Nigeria
Viking Therapeutics Raises $547.8 Million via Equity Sale and 2.00% Convertible Notes - TradingView
Viking Therapeutics nets ~$550M in proceeds from latest offering - TradingView
Viking Therapeutics raises $575 million in dual offering - Investing.com
Viking Therapeutics raises $575 million in dual offering By Investing.com - Investing.com Australia
Viking Therapeutics (VKTX) Closes Upsized Stock and 2.00% Convertible Notes Offerings, ~$575M Gross - TradingView
Viking Therapeutics, Inc. Bonds — Corporate Bond Rates - TradingView
Viking Therapeutics (VKTX): VK2735 Data Look Strong, but Cash Burn Still Matters - AlphaStreet
Viking Therapeutics posts strong obesity drug t... - Pluang
Viking Therapeutics Draws Investor Investigations - stl.news
Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver (VKTX) - Seeking Alpha
Investigation launched into Viking Therapeutics' officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm - Morningstar
Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly? - The Motley Fool
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? - Yahoo Finance
Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution - Yahoo Finance
VKTX Stock Eyes Blockbuster Week Despite Share Offering — Retail Traders See A Stronger Hand In Buyout Talks - Stocktwits
3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing - Yahoo Finance
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
VKTX Stock Reverses Weight-Loss Drug Gains As Viking Unveils $500M Discounted Financing - Stocktwits
VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users? - Stocktwits
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t - Stocktwits
Viking Therapeutics Stock (VKTX) Opinions on Positive Obesity Drug Data Release - Quiver Quantitative
What Viking Therapeutics Stock Means For Shareholders After Obesity Drug Data And $500 Million Raise - simplywall.st
VKTX 10-Q FilingsViking Therapeutics, Inc SEC 10-Q - Stock Titan
Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver (NASDAQ:VKTX) - Seeking Alpha
Is Viking Therapeutics (VKTX) Getting Too Rich After VK2735 Data? - Yahoo Finance
Biotech Stocks To ResearchSeptember 25th - MarketBeat
VKTX Form 4 FilingsViking Therapeutics, Inc SEC Form 4 - Stock Titan
Is Viking Therapeutics, Inc. (VKTX) the Healthcare Stocks Stock Everyone's About to Talk About? - Kalkine Media
Form 424B5 Viking Therapeutics Inc For: 25 September - Investing.com India
Latham Advises on Viking Therapeutics’ Upsized US$500 Million Offering of Common Stock and Convertible Senior Notes - Legal Desire
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? - The Motley Fool
Form 424B5 Viking Therapeutics Inc For: 25 September By Investing.com - Investing.com Canada
VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress - Stocktwits
Viking Therapeutics (VKTX) Stock Looks Fully Priced Despite Its Huge Five Year Run - simplywall.st
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Viking Therapeutics Plunges After Upsized $500 Million Financing Prices at 16% Discount - finance.biggo.com
Viking Therapeutics Share Drop After Upsized Stock, Notes Offerings - moomoo.com
One investor reportedly took a third of Viking’s share sale - Yahoo Finance Australia
Viking Therapeutics raises USD 500m to advance VK2735 obesity program - AllSci
Latham Advises on Viking Therapeutics Upsized Offering of Common Stock and Convertible Senior Notes - Latham & Watkins LLP
Viking Therapeutics Advances VK2735 Obesity Trial, Keeping VKTX in the Weight Loss Race - TipRanks
Here's Why Viking Therapeutics Shares Slumped Today - The Motley Fool
Top Biotech Stocks To Keep An Eye OnSeptember 24th - MarketBeat
Why Is Viking Therapeutics Stock Trading Down Thursday? - Benzinga
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):